Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Vertex to seek approval of IgAN drug after Phase III success

Vertex will use a priority review voucher to expedite the approval of povetacicept in IgAN.

Latest news

EnteroBiotix completes enrolment in Phase IIa MAST trial

Imperial College London is sponsoring the study while the Medical Research Council is providing funding.

Building for decades: Dubai’s long game in life sciences

The emirate's healthcare ambitions are soaring, but cultivating local research and innovation remains the ultimate test.

Kainova reports positive top line results from Phase I EPRAD trial

The study demonstrated a favourable safety profile for DT-9081.

Analysts tout market potential of Xenon’s epilepsy drug on Phase III win

Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.

Roche’s oral SERD fails in Phase III breast cancer trial

In the study, giredestrant showed no statistical improvement in the primary endpoint, but there was a numerical improvement.